Semaglutide Biosimilar | C074P

Catalog No.	C074P
Product Name	Semaglutide Biosimilar | C074P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Acylated Glucagon-like Peptide-1 Receptor Agonist, Human GLP-1 Receptor Agonist, Human GLP-1 Analog
Source/Host	The recombinant peptide semaglutide biosimilar was produced in the semaglutide stable cell line.
Endotoxin	< 1 EU per 1 mg of the peptide by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade semaglutide biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Semaglutide biosimilar stable cell line is available for licensing to manufacture the semaglutide biosimilar. The research grade semaglutide biosimilar is for research use only (RUO).
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C074P: Semaglutide Biosimilar
Background

What is research grade semaglutide biosimilar? Research grade semaglutide biosimilar has the same amino acid sequence as semaglutide, a recombinant peptide which presents 94% sequence homology to the human glucagon-like peptide-1 (GLP-1), differing primarily by two amino-acid substitutions at positions 8 and 34, where alanine and lysine are replaced by 2-aminoisobutyric acid and arginine, respectively. Liraglutide is made by attaching a C-18 fatty acid (stearic diacid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Semaglutide is resistant to the dipeptidylpeptidase-4 enzyme whic degrades the natural hormone. As a GLP-1 receptor agonist, Semaglutide mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control. Semaglutide is an anti-diabetic medication used to treat type 2 diabetes, obesity, and chronic weight management.

Syd Labs also provides the following GLP-1 receptor agonist biosimilar peptide:
Liraglutide biosimilar

Please remember our product information: Semaglutide Biosimilar: C074P Syd Labs

No more offers for this product!